The company’s target is aminopeptidase N (CD13) located on cells of the tumor vasculature and some tumor cells, but absent from most mature blood vessels. The company’s founders have designed and studied truncated tissue factor (tTF) with a C- terminal GNGRAHA peptide (tTF-NGR) binding to CD13 and causing tumor vascular thrombosis with subsequent tumor infarction.
The company is currently carrying out a Phase II/III study for patients with soft tissue sarcoma. Since tTF-NGR targets the tumor vasculature, which is similar in different tumor types, the principle of entrapping tumor therapeutics by tTF-NGR induced vascular occlusion, if successful in the active trial, may be be generalized as a treatment modality for multiple vascularized tumor entities.
In addition to the clinical lead structure tTF-NGR, the company has active preclinical programs on other targeted proteins and nucleic acids.
Subscribe for alerts on new companies featured on Startups.Bio
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
